Cargando…

A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells

Cisplatin (ddp), which is commonly employed in the treatment of many advanced cancers, often results in initial therapeutic success; however, rapid progression of ddp-resistant cells remains the main reason for treatment failure. Facd with such a problem, we investigated the fitness differences betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duan, Guihua, Tang, Qianyuan, Yan, Hongli, Xie, Lijuan, Wang, Yun, Zheng, Xi Emily, Zhuge, Yuzheng, Shen, Shanshan, Zhang, Bin, Zhang, Xiaoqi, Wang, Jun, Wang, Wei, Zou, Xiaoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428423/ https://www.ncbi.nlm.nih.gov/pubmed/28348367 http://dx.doi.org/10.1038/s41598-017-00422-2

Ejemplares similares

Increased Glutamine Consumption in Cisplatin-Resistant Cells Has a Negative Impact on Cell Growth
por: Duan, Guihua, et al.
Publicado: (2018)

Increased Autophagy Levels Mediate Cisplatin Resistance in Cisplatin-Resistant Cells While Also Rendering Them Vulnerable to Autophagy Induction
por: Duan, Guihua, et al.
Publicado: (2018)

Magnesium Isoglycyrrhizinate Reduces the Target-Binding Amount of Cisplatin to Mitochondrial DNA and Renal Injury through SIRT3
por: Wang, Xinyu, et al.
Publicado: (2022)

Inhibition of AEBP1 predisposes cisplatin-resistant oral cancer cells to ferroptosis
por: Zhou, Qianwen, et al.
Publicado: (2022)

S-Adenosylmethionine suppresses the expression of Smad3/4 in activated human hepatic stellate cells via Rac1 promoter methylation
por: BIAN, KANGQI, et al.
Publicado: (2016)

Proposal to increase the Amounts of Certain Temporary Labour Contracts
Publicado: (1983)

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC
por: Tang, Zuxiong, et al.
Publicado: (2021)

Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment
por: Xiao, Xiao, et al.
Publicado: (2019)

The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin
por: Su, Haochen, et al.
Publicado: (2023)

Regulation of AKT gene expression by cisplatin
por: ZHANG, JUN, et al.
Publicado: (2013)

Cisplatin‐incorporated Polymeric Micelles Eliminate Nephrotoxicity, While Maintaining Antitumor Activity
por: Mizumura, Yasuo, et al.
Publicado: (2001)

GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin
por: Gong, Xin, et al.
Publicado: (2017)

SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line
por: Zhang, Yongli, et al.
Publicado: (2016)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer
por: Xiao, Xiaoguang, et al.
Publicado: (2015)

Astaxanthine attenuates cisplatin ototoxicity in vitro and protects against cisplatin-induced hearing loss in vivo
por: Nan, Benyu, et al.
Publicado: (2022)

Sonophoresis Enhanced Transdermal Delivery of Cisplatin in the Xenografted Tumor Model of Cervical Cancer
por: Ma, Shanshan, et al.
Publicado: (2020)

Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma
por: Hu, Lijuan, et al.
Publicado: (2017)

Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy
por: Lv, Xiaojie, et al.
Publicado: (2016)

Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin
por: Nicolay, Nils H., et al.
Publicado: (2016)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence
por: Iram, Sana, et al.
Publicado: (2019)

Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects
por: Wang, Zhu, et al.
Publicado: (2023)

Liver cirrhosis caused by chronic Budd–Chiari syndrome
por: Lin, Mengjie, et al.
Publicado: (2017)

Discovery of cisplatin-binding proteins by competitive cysteinome profiling
por: Wang, Xianghe, et al.
Publicado: (2023)

Self-enforcing HMGB1/NF-κB/HIF-1α Feedback Loop Promotes Cisplatin Resistance in Hepatocellular Carcinoma Cells
por: Song, Yang, et al.
Publicado: (2020)

EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer
por: Wang, Xuemin, et al.
Publicado: (2015)

Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells
por: Sui, Yanxia, et al.
Publicado: (2015)

Cisplatin induces loop structures and condensation of single DNA molecules
por: Hou, Xi-Miao, et al.
Publicado: (2009)

Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells
por: Fujii, Ryu‐ichi, et al.
Publicado: (1994)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
por: Matsui, K., et al.
Publicado: (1996)

Correction: EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer
por: Wang, Xuemin, et al.
Publicado: (2015)

Overweight/Obesity Increases the Risk of Overt Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients
por: Gu, Lihong, et al.
Publicado: (2023)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022)

The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses
por: Cao, Yu, et al.
Publicado: (2018)

lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma
por: Chen, Jie, et al.
Publicado: (2020)

BNIP3 contributes to cisplatin‐induced apoptosis in ovarian cancer cells
por: Jia, Jinghui, et al.
Publicado: (2020)

Cisplatin in breast cancer.
por: Willemse, P., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_orhqet2plvnfcu36mfrqpo3j5n